Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178545546> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2178545546 endingPage "GRHTA.5000194" @default.
- W2178545546 startingPage "GRHTA.5000194" @default.
- W2178545546 abstract "Chronic inflammatory diseases, while seriously impairing patients' quality of life, are a heavy financial cost to the National Health Service (NHS) and to society. The availability of biological drugs – among which infliximab (Remicade®) – greatly improved treatment efficacy. On the other hand, these drugs are an expensive resource. Infliximab patent protection is going to expire, and a biosimilar has been recently approved. A budget impact (BI) analysis was conducted to evaluate the favourable consequences – for the Italian NHS – of the biosimilar availability in terms of cost containment (savings), thanks to its lower price compared to the originator's. The analysis model expects that some patients in treatment with the originator will switch (according to a prudent assumption of the market uptake rate) to the biosimilar and that many naïve patients will directly start treatment with the biosimilar (according to a bolder uptake rate assumed). Separately considering all the different diseases for which infliximab is indicated, the number of patients who might potentially use the biosimilar is estimated – based on disease prevalence and incidence rates, the overall proportion of treated patients and the infliximab market share. The time horizon extends to five years (starting from 2015). The biosimilar price discount is 25%. The results from the analysis show (in the base case) that the availability of the biosimilar would provide overall annual savings over €16 million to the NHS in 2019, while the cumulated savings in the five years period would be no less than €47 million. The sensitivity analysis highlights that such favourable results would be even more substantial, to the extent that switching from originator to biosimilar could be safely recommended." @default.
- W2178545546 created "2016-06-24" @default.
- W2178545546 creator A5006429617 @default.
- W2178545546 creator A5009729828 @default.
- W2178545546 creator A5053288231 @default.
- W2178545546 date "2015-05-01" @default.
- W2178545546 modified "2023-09-26" @default.
- W2178545546 title "Budget impact analysis of infliximab biosimilar: the Italian scenery" @default.
- W2178545546 cites W147282538 @default.
- W2178545546 cites W1476301056 @default.
- W2178545546 cites W1488219765 @default.
- W2178545546 cites W1965347749 @default.
- W2178545546 cites W2021018799 @default.
- W2178545546 cites W2030481979 @default.
- W2178545546 cites W2061911339 @default.
- W2178545546 cites W2082746297 @default.
- W2178545546 cites W2085136989 @default.
- W2178545546 cites W2100222785 @default.
- W2178545546 cites W2102987799 @default.
- W2178545546 cites W2111948020 @default.
- W2178545546 cites W2121025314 @default.
- W2178545546 cites W2121050884 @default.
- W2178545546 cites W2157008349 @default.
- W2178545546 cites W2162768160 @default.
- W2178545546 cites W2168250184 @default.
- W2178545546 cites W2276875976 @default.
- W2178545546 cites W2313219699 @default.
- W2178545546 cites W2978875517 @default.
- W2178545546 cites W4235670806 @default.
- W2178545546 cites W4238512125 @default.
- W2178545546 cites W4249208671 @default.
- W2178545546 doi "https://doi.org/10.5301/grhta.5000194" @default.
- W2178545546 hasPublicationYear "2015" @default.
- W2178545546 type Work @default.
- W2178545546 sameAs 2178545546 @default.
- W2178545546 citedByCount "5" @default.
- W2178545546 countsByYear W21785455462017 @default.
- W2178545546 countsByYear W21785455462019 @default.
- W2178545546 countsByYear W21785455462021 @default.
- W2178545546 crossrefType "journal-article" @default.
- W2178545546 hasAuthorship W2178545546A5006429617 @default.
- W2178545546 hasAuthorship W2178545546A5009729828 @default.
- W2178545546 hasAuthorship W2178545546A5053288231 @default.
- W2178545546 hasBestOaLocation W21785455461 @default.
- W2178545546 hasConcept C10138342 @default.
- W2178545546 hasConcept C126322002 @default.
- W2178545546 hasConcept C144133560 @default.
- W2178545546 hasConcept C162118730 @default.
- W2178545546 hasConcept C177713679 @default.
- W2178545546 hasConcept C2777138892 @default.
- W2178545546 hasConcept C2779134260 @default.
- W2178545546 hasConcept C28761237 @default.
- W2178545546 hasConcept C59491497 @default.
- W2178545546 hasConcept C71924100 @default.
- W2178545546 hasConceptScore W2178545546C10138342 @default.
- W2178545546 hasConceptScore W2178545546C126322002 @default.
- W2178545546 hasConceptScore W2178545546C144133560 @default.
- W2178545546 hasConceptScore W2178545546C162118730 @default.
- W2178545546 hasConceptScore W2178545546C177713679 @default.
- W2178545546 hasConceptScore W2178545546C2777138892 @default.
- W2178545546 hasConceptScore W2178545546C2779134260 @default.
- W2178545546 hasConceptScore W2178545546C28761237 @default.
- W2178545546 hasConceptScore W2178545546C59491497 @default.
- W2178545546 hasConceptScore W2178545546C71924100 @default.
- W2178545546 hasIssue "2" @default.
- W2178545546 hasLocation W21785455461 @default.
- W2178545546 hasLocation W21785455462 @default.
- W2178545546 hasOpenAccess W2178545546 @default.
- W2178545546 hasPrimaryLocation W21785455461 @default.
- W2178545546 hasRelatedWork W1981336058 @default.
- W2178545546 hasRelatedWork W2328722664 @default.
- W2178545546 hasRelatedWork W2586347026 @default.
- W2178545546 hasRelatedWork W2587157414 @default.
- W2178545546 hasRelatedWork W2774189845 @default.
- W2178545546 hasRelatedWork W2799488547 @default.
- W2178545546 hasRelatedWork W2944483536 @default.
- W2178545546 hasRelatedWork W4231459691 @default.
- W2178545546 hasRelatedWork W4253615316 @default.
- W2178545546 hasRelatedWork W4379521643 @default.
- W2178545546 hasVolume "2" @default.
- W2178545546 isParatext "false" @default.
- W2178545546 isRetracted "false" @default.
- W2178545546 magId "2178545546" @default.
- W2178545546 workType "article" @default.